With the factor XI inhibitor, clinicians may have more flexibility when managing anticoagulation in this common scenario.

The combination will be available in several doses and is also approved as a first-line option for patients with hypertension ...

Karmpaliotis leaves behind a legacy of teaching his profound skills in complex PCI and his passion for patients and family.

The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The aim is to “activate these guidelines in a way that they become more actionable for clinicians,” Harlan Krumholz says.

The lack of effect shouldn’t detract from MINT, which showed a strong trend toward benefit with liberal blood transfusion.

Female shock patients face delays in treatment and are less likely to receive approved interventions, says Suzanne Baron.

This explains at least some of the racial/ethnic gaps in survival, researchers say. Harder to pinpoint is exactly why ...

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

With new CVD treatments arriving each year, “there’s no reason why outcomes should be getting worse,” says Jason Wasfy.